Posted: 28 October 2025
A new international collaboration between Myrio Therapeutics, the University of Pennsylvania’s Perelman School of Medicine, and NYU Langone Health has been formed to accelerate the development of next-generation T cell immunotherapies targeting solid tumours.
The partnership united global expertise in peptide HLA (pHLA) binder discovery, bispecific T-cell engager development, and cell-based immunotherapies, with a shared goal of overcoming key barriers to durable cancer treatment. Together, the organisations aimed to advance three major research pillars: targeting oncogenic drivers using highly specific anti-pHLA antibodies, amplifying innate immune responses, and utilising novel Chimeric Antigen Receptor (CAR) architectures to improve therapeutic reach and sensitivity.
Dr Graeme Wald, Chief Executive Officer of Myrio Therapeutics, said the collaboration represented a significant step forward for the field. “This is a magnificent case of putting the best technologies and people together to develop products for solid tumour treatments,” he said. “The next step will be to formally establish a company and initiate seed funding to move these advances toward clinical development.”
Professor Daniel J Powell Jr., from the University of Pennsylvania’s Perelman School of Medicine, said the collaboration addressed one of oncology’s greatest challenges. “A major challenge in the development of cancer treatment is creating tolerable approaches that also deliver effective and long-lasting response in patients,” he said. “By uniting the diverse expertise of these three groups, we are in an excellent position to create safe, effective, durable therapy for difficult-to-treat cancers.”
NYU Langone Health’s Assistant Professor Mark Yarmarkovich added that combining complementary technologies provided “an opportunity to create truly differentiated therapies that can change the treatment landscape and, most importantly, make a meaningful difference for patients.”
The partners confirmed plans to establish a new entity and secure seed funding to progress these innovations toward clinical development.
